Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) shares hit a new 52-week low during mid-day trading on Monday . The company traded as low as $9.88 and last traded at $11.49, with a volume of 13183 shares trading hands. The stock had previously closed at $10.99.
Analyst Upgrades and Downgrades
Several research firms recently commented on MAZE. TD Cowen raised shares of Maze Therapeutics to a "strong-buy" rating in a research note on Tuesday, February 25th. Leerink Partnrs raised shares of Maze Therapeutics to a "strong-buy" rating in a research report on Tuesday, February 25th. JPMorgan Chase & Co. assumed coverage on shares of Maze Therapeutics in a research note on Tuesday, February 25th. They set an "overweight" rating and a $30.00 price target for the company. Leerink Partners began coverage on Maze Therapeutics in a research note on Tuesday, February 25th. They issued an "outperform" rating and a $28.00 price objective on the stock. Finally, Guggenheim initiated coverage on Maze Therapeutics in a research report on Tuesday, February 25th. They set a "buy" rating and a $19.00 target price for the company. Three research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, Maze Therapeutics currently has a consensus rating of "Buy" and a consensus price target of $25.67.
View Our Latest Stock Report on MAZE
Maze Therapeutics Stock Down 6.9 %
Maze Therapeutics Company Profile
(
Get Free Report)
We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.
Further Reading
Before you consider Maze Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Maze Therapeutics wasn't on the list.
While Maze Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
